Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Berkeley

(Sharecast News) - Analysts at Berenberg lowered their target price on housebuilder Berkeley Group from 5,500.0p to 5,000.0p on Monday following its FY25 results on 20 June. Berenberg said that if one simply focuses on the near-term, it acknowledged that the Berkeley investment thesis faces headwinds. Most notably, the German bank said near-term headwinds stemmed from Berkeley's longer-duration model, delivering a further decline in profit in 2026, and noted that the company's strategic move into build-to-rent could "pressure returns" in the near term.

However, over the medium-term, Berenberg sees "a compelling proposition" and thinks that Berkeley's position as a developer of large, complex urban regeneration schemes presents "significant growth opportunities", while its margin resilience in recent years illustrates its financial discipline.

"With the company trading at the low end of its 20-year TNAV multiple range, we remain positive, albeit noting the lack of near-term positive catalysts," said Berenberg, which reiterated its 'buy' rating on the stock.

Berenberg also highlighted that the company had confirmed its Berkeley 2035 strategic plan to put £2.0bn towards its 4,000-unit build-to-rent portfolio, allocate a further £2.0bn to shareholder returns, and make a final £1.3bn available to allocate to either of the aforementioned on an opportunistic basis. Berenberg noted that Berkeley was pleased with the early progress of its buy-to-rent portfolio as it discussed possible options to crystallise the value of the asset in the future.

"We note that its minimum shareholder return is equal to 5% per year, at current market cap, over the next 10 years, while it could be as high as 8% per year if the flexible £1.3bn is also returned to shareholders," added Berenberg.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.